Your browser doesn't support javascript.
loading
XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer:a retrospective study / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics ; (6): 68-70,73, 2014.
Artículo en Chino | WPRIM | ID: wpr-553773
ABSTRACT
Objective To observe the efifcacy and safety of XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer. Methods In this study, we retrospectively reviewed cases in which XELOX plus bevacizumab were administered in order to evaluate its efifcacy and safety in clinical practice.In total, 40 patients with mCRC who presented at Fuchu Hospital received XELOX plus bevacizumab as a ifrst?line treatment from September, 2009 to April, 2012. Eligible patients had histologically conifrmed mCRC. XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 plus oral capecitabine 1,000 mg/m 2 twice daily for two weeks of athree?week cycle. Overall survival (OS) and survival benefit were analyzed when patients continued with XELOX plus bevacizumab beyond disease progression. Results The median progression?free survival (PFS) was 290 days [95%conif-dence interval (CI)222?409 days] and the median OS was 816 days (95%CI490?842 days). The response rate (RRcomplete plus partial response) was 67.5%, and the disease control rate (RR plus stable disease) was 90%. Conclusion XELOX plus bevacizumab may be considered a routine ifrst?line treatment option for patients with mCRC.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Estudio observacional Idioma: Chino Revista: Chinese Journal of Biochemical Pharmaceutics Año: 2014 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Estudio observacional Idioma: Chino Revista: Chinese Journal of Biochemical Pharmaceutics Año: 2014 Tipo del documento: Artículo